Lakefront Biotherapeutics (LKFT) Current Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Current Assets data on file, last reported at $3.6 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $3.6 billion, down 1.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 1.89% YoY), and the FY2025 annual result was $3.6 billion, changed 0.45% from the prior year.
• Current Assets was little changed at $3.6 billion in Q1 2026 per LKFT's latest filing, from $3.6 billion in the prior quarter.
• Over five years, Current Assets peaked at $5.3 billion in Q1 2022 and troughed at $3.6 billion in Q4 2024.
• A 5-year average of $4.0 billion and a median of $3.9 billion in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets decreased 22.28% in 2022, then climbed 0.45% in 2025.
• A 5-year view of Current Assets shows it stood at $4.3 billion in 2022, then fell by 3.88% to $4.2 billion in 2023, then fell by 14.11% to $3.6 billion in 2024, then rose by 0.45% to $3.6 billion in 2025, then fell by 0.04% to $3.6 billion in 2026.
• Business Quant data shows LKFT's Current Assets at $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.7 billion in Q3 2025.